Plain-English translation of NCT05517135 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a new approach to treating nasopharyngeal cancer — a cancer of the tissue behind the nose. Researchers believe that measuring EBV (a virus linked to this cancer) in a patient's blood before and during treatment can help doctors choose the right intensity of therapy for each person. The study will assign patients to different treatment plans based on their EBV levels to see if this personalized approach helps people live longer and stay cancer-free.
Nasopharyngeal cancer patients receive very different outcomes with standard treatment, and doctors don't currently have a reliable way to predict who will do well and who might relapse. This trial exists to see if EBV virus levels in the blood can serve as a guide to tailor treatment intensity, potentially sparing some patients from unnecessary harsh therapy while giving more aggressive treatment to those who need it most.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will have blood tests to measure your EBV virus levels before treatment starts and after a few cycles of chemotherapy. Based on your EBV levels, you will be assigned to one of three treatment plans of varying intensity. You will then undergo your assigned cancer treatment — which may include chemotherapy, radiation, or both — and return for regular follow-up visits and blood tests. The study will track whether you remain cancer-free for at least 2 years after treatment.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
Singapore
Sponsor
National Cancer Centre, Singapore
Enrollment target
~1,000 participants
Started
November 2022
Primary completion
July 2027
Age range
21 Years – 99 Years
Last updated on clinicaltrials.gov in September 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Melvin Lee Kiang Chua, MBBS, FRCR, PhD, FAMS
National Cancer Centre, Singapore
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.